XML 43 R30.htm IDEA: XBRL DOCUMENT v3.22.4
Stockholders’ Equity and Stock-Based Compensation (Tables)
12 Months Ended
Dec. 31, 2022
Equity [Abstract]  
Schedule of Non-vested Restricted Stock Activity

 

   Shares  

Weighted Average

Grant Fair Value

 
Balance at December 26, 2020   3,051,874   $1.67 
Granted   2,247,343    3.46 
Forfeited   (1,654,666)   2.03 
Vested   (1,566,959)   2.23 
Balance at December 25, 2021   2,077,592    2.90 
Granted   1,013,600    1.33 
Forfeited   (444,350)   2.45 
Vested   (680,941)   2.82 
Balance at December 31, 2022   1,965,901   $2.22 
Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions

 

Expected volatility   94.2%
Interest rate   0.2%
Expected life (years)   0.7 
Dividend yield   %
Schedule of Stock-based Compensation Expense

The following table summarizes stock-based compensation expense within each of the categories below as it relates to non-vested restricted common stock awards for the fiscal years 2022, 2021 and 2020 (no tax benefits were recognized):

 

   2022   2021   2020 
Cost of product revenues  $94,634   $211,362   $113,517 
Research and development   435,842    576,193    204,599 
Selling, general and administrative   737,229    3,629,867    503,006 
Total  $1,267,705   $4,417,422   $821,122